Daniel P Hart
Overview
Explore the profile of Daniel P Hart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
1077
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Astermark J, Blatny J, Konigs C, Hermans C, Jimenez-Yuste V, Hart D
Ther Adv Hematol
. 2023 Apr;
14:20406207231165857.
PMID: 37113810
Plain Language Summary: Medical advances are providing a range of treatment options for adults and children with hemophilia. There is, however, relatively limited information about managing newborns with the condition....
2.
Pipe S, Leebeek F, Recht M, Key N, Castaman G, Miesbach W, et al.
N Engl J Med
. 2023 Feb;
388(8):706-718.
PMID: 36812434
Background: Moderate-to-severe hemophilia B is treated with lifelong, continuous coagulation factor IX replacement to prevent bleeding. Gene therapy for hemophilia B aims to establish sustained factor IX activity, thereby protecting...
3.
Wall C, Xiang H, Palmer B, Chalmers E, Chowdary P, Collins P, et al.
Haemophilia
. 2023 Feb;
29(3):743-752.
PMID: 36811304
Introduction: The UK National Haemophilia Database (NHD) collects data from all UK persons with haemophilia A with inhibitors (PwHA-I). It is well-placed to investigate patient selection, clinical outcomes, drug safety...
4.
Hart D, Matino D, Astermark J, Dolan G, dOiron R, Hermans C, et al.
Ther Adv Hematol
. 2022 Apr;
13:20406207221085202.
PMID: 35392437
Haemophilia B is a rare X-linked genetic deficiency of coagulation factor IX (FIX) that, if untreated, can cause recurrent and disabling bleeding, potentially leading to severe arthropathy and/or life-threatening haemorrhage....
5.
Miesbach W, Baghaei F, Boban A, Chowdary P, Coppens M, Hart D, et al.
Haemophilia
. 2022 Mar;
28(3):e86-e88.
PMID: 35263819
No abstract available.
6.
Escobar M, Luck J, Averianov Y, Ducore J, Lopez Fernandez M, Giermasz A, et al.
Haemophilia
. 2021 Oct;
27(6):911-920.
PMID: 34614267
Introduction: Surgical procedures in persons with haemophilia A or B with inhibitors (PwHABI) require the use of bypassing agents (BPA) and carry a high risk of complications. Historically, only two...
7.
Kloosterman F, Abdi A, Gouw S, Hart D, Fijnvandraat K
J Thromb Haemost
. 2021 Sep;
19(10):2642-2644.
PMID: 34558782
No abstract available.
8.
Miesbach W, Chowdary P, Coppens M, Hart D, Jimenez-Yuste V, Klamroth R, et al.
Haemophilia
. 2021 Sep;
27(6):967-973.
PMID: 34553460
Introduction: Adeno-associated virus (AAV)-based gene therapy for haemophilia presents a challenge to the existing structure of haemophilia centres and requires a rethink of current collaboration and information exchange with the...
9.
10.
Hart D, Alamelu J, Bhatnagar N, Biss T, Collins P, Hall G, et al.
Haemophilia
. 2021 Aug;
27(6):932-937.
PMID: 34403546
Introduction: In good risk patients (historic inhibitor peak < 200BU), the International Immune Tolerance Study demonstrated equal efficacy to induce tolerance between high (200iu/kg/day) and low dose (50iu/kg ×3 times/week)...